Immunocore to present at upcoming investor conferences

Rhea-AI Summary

Immunocore Holdings Plc announced that management will present at several investor conferences in November. The conferences include TD Cowen Fall Oncology Innovation Summit, Truist Securities BioPharma Symposium, Jefferies London Healthcare Conference, and 3rd Annual BTIG Ophthalmology Day. The presentations will be webcast live and can be accessed on Immunocore's website. A replay of the presentations will also be available for a limited time.

Immunocore to present at upcoming investor conferences

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 30 October 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune conditions, today announced that management will present at the following investor conferences in November:

• TD Cowen Fall Oncology Innovation Summit: Insights for SITC and ASH
  Fireside Chat: Friday, November 3, 2023, at 2:20 p.m. EDT
  

• Truist Securities BioPharma Symposium
  1x1 and small group meetings: Wednesday, November 8, 2023
  

• Jefferies London Healthcare Conference
  Fireside Chat: Tuesday, November 14, 2023, at 2:30 p.m. GMT
  

• 3^rd Annual BTIG Ophthalmology Day
  Fireside Chat: Monday, November 27, 2023, at 10:30 a.m. EST
  

Where relevant, the presentations will be webcast live and can be accessed by visiting ‘Events’, under ‘News & Events’, via the ‘Investors’ section of Immunocore’s website at www.immunocore.com. Following the events, a replay of the presentations will be made available for a limited time.

##

About Immunocore

Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune, and infectious disease. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including four clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.

CONTACT: 

Immunocore
Sébastien Desprez, Head of Communications
T: +44 (0) 7458030732
E: sebastien.desprez@immunocore.com
Follow on Twitter: @Immunocore

Investor Relations  
Clayton Robertson, Head of Investor Relations
T: +1 215-384-4781
E: ir@immunocore.com

FAQ

Which company is presenting at the investor conferences in November?

Immunocore Holdings Plc.

What are the names of the investor conferences?

The investor conferences are TD Cowen Fall Oncology Innovation Summit, Truist Securities BioPharma Symposium, Jefferies London Healthcare Conference, and 3rd Annual BTIG Ophthalmology Day.

Where can the presentations be accessed?

The presentations can be accessed on Immunocore's website under the 'Events' section in the 'Investors' section.

Will there be a replay of the presentations?

Yes, a replay of the presentations will be made available for a limited time.